Leading the Way in Diabetes Care, and in the Discussion of How to Pay for It
Published Online: December 16, 2013
An Interview with John L. Brooks III, CEO and President, Joslin Diabetes Center
John L. Brooks III, CEO and president of Joslin Diabetes Center in Boston, Massachusetts, hosted the center’s second “Diabetes Innovation” conference in Washington, DC, October 2-5, 2013. As host, Brooks welcomed 485 attendees and more than 40 speakers from across the stakeholder community: patients, providers, payers, leaders in research and policy, and even social media. (Please see our Special Report: Diabetes Innovation 2013, a supplement from The American Journal of Managed Care.)
Below are excerpts from Brooks’ interview with Evidence-Based Diabetes Management, which took place during the conference. Excerpts have been edited and condensed for clarity.
EBDM: As we meet, there is news about a device, Medtronic’s 530G “Threshold Suspend,” the first system that the FDA has approved with the name “artificial pancreas.” Can you describe your role, and Joslin’s role, in talking to payers about making sure that persons with diabetes have access to the most current technology?
Brooks: New technology usually has a cost associated with it. We want to make sure our patients, whether they are type 1 or type 2, have the best technology so they can check their blood, so we can make sure they are taking their medications and make sure that if they are on insulin they get the right amount. We want to use technology to keep them motivated and positive. All that technology has a cost element to it.
The bottom line is: how do we show that it’s cost-effective? How do we show that a new technology not only makes a difference—that it produces better outcomes, that it helps our patients and their families better manage their disease—but also, in today’s day and age, it requires good economic measures. We have to show that new technology, even if it costs a little more, it leads to better results—that it’s going to take cost and economics out of the equation.
Sometimes that’s a bit of a chicken-and-the-egg question. That’s where Joslin comes in. We are happy to work with companies, payers, or providers to do a pilot study. We can ask, “How can we do a small study that shows this new technology makes a difference, that it’s helping patients and their families do a better job managing diabetes, it’s keeping them healthy and keeping their numbers where they should be and hopefully keeping them out of emergency department visits. And, can we quantify that?” Once we do that, we have proof, and we can go to payers and say, “Look, here’s a good argument that we’ve been able to validate, so you should feel comfortable allowing diabetes patients to have access to this new technology.”
Sometimes it may be more money up front, but it will pay big dividends downstream. However, you can’t just say, “We want to use new technology;” you have to have that hypothesis in place; at Joslin, we are able to prove economic validity.
EBDM: More persons with diabetes who perhaps have been locked out of the insurance system might gain access with the opening of the exchanges under the Affordable Care Act. What is that going to mean for Joslin, and for the diabetes community generally?
Brooks: In Boston, where we are located physically, we see about 25,000 patients a year; Massachusetts has had full access to healthcare for a number of years, so we have a good understanding of what is going to happen now that the ACA is in place. Nationally, we are going to see more people come into the health system; maybe they weren’t getting full care, maybe they were on the edge of having access to care. As they enroll, they become part of the health system.
We want to educate our diabetes patients as they enroll. When persons with diabetes look at their choices on the exchanges, it’s important that they make sure they don’t just take the cheapest plan or the one that “looks like” it works. Given that they have a chronic disease, persons with diabetes are going to have to do a little more drilling. They should make sure the plan they choose has not only the right economics, but also that it offers the right type of care, the right level of coverage, and the support they need to manage their disease. For those with diabetes and prediabetes or obesity, we encourage them to go on the exchanges. But we want to educate patients, so the plan they choose is comprehensive enough; we don’t want to see people sign up for something and learn later it’s not ideal for their disease management, or that it ends up costing them more than they expected (in copays or other out-of-pocket costs).
EBDM: In June the American Medical Association took the step of declaring obesity a disease, after other organizations already had. What is the significance of that declaration for clinicians who are treating persons with diabetes or prediabetes and obesity?
Brooks: One of the interesting phenomena around type 2 diabetes (T2DM) and obesity is the misconception that if people just hunker down they can get rid of this disease on their own. We’ve come to realize that obesity is a complicated process; there is a genetic component. People’s genes can predispose them to the likelihood of becoming obese and perhaps progressing to diabetes. The fact that the American Medical Association has said obesity is a disease—that it’s not just lifestyle driven, although that is part of it—means that it needs medical attention.
At this conference, we are talking about giving our primary care doctors more tools, more resources, and more education, so they understand the ways they can help persons at risk for diabetes or obesity. The prescription can’t be, “Lose weight and exercise.” That has to be translated into, “Let’s talk about what type of exercise. Let’s talk about your diet; let’s talk about the foods you are consuming. What resources do we have available for you? Are there some apps you can follow?” The key is, we recognize it’s a medical problem that needs medical attention; it needs the support of the ecosystem: the payers, the providers, and the community.
At Joslin, we feel that’s going to be important if we’re going to stop this progression. There are 78 million people in the United States at risk of developing diabetes, and 26 million with diabetes. The projections suggest that by 2050, if we don’t get our act together, we could have 1 in 3 people with diabetes. That’s not a good answer. We need more resources and more focus to stop this pandemic.
PDF is available on the last page.